ArticleJTCVS open2025
Acute kidney injury and chronic kidney disease after left ventricular assist device placement.
Article in JTCVS open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- SGLT2 inhibitors and outcomes in the chronic Post-LVAD phase: a multicenter real-world cohort study.Frontiers in pharmacology · 2026Article
- Chronic kidney disease following left ventricular assist device implantation: contemporary insights and future perspectives.Heart failure reviews · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Objective: Left ventricular assist device (LVAD) implantation may lead to acute kidney injury (AKI), but LVAD therapy increases cardiac output and may reverse cardiorenal syndrome. We conducted this study to test the hypothesis that AKI after LVAD implantation is associated with glomerular filtration rate (eGFR) decline and chronic kidney disease (CKD) stage progression. Methods: We included all patients undergoing LVAD implantation between August 2011 and August 2021 at a high-volume LVAD center. AKI was quantified using Kidney Disease: Improving Global Outcomes criteria. We estimated eGFR before and 30, 60, 90, and 365 days after LVAD implantation to stage CKD. We measured the associations between AKI and eGFR, adjusting for potential confounders and risk factors. Results: One hundred ninety-one of the 482 subjects (39.6%) developed postoperative AKI. Overall, median eGFR change (25th, 75th percentile) was -5.9% (-22.3%, 15.6%) at 90 days after LVAD and -17.2% (-36.9%, 5.1%) at 1 year. In subjects who developed AKI, eGFR declined 11.7% (95% confidence interval, 4.2%-19.1%; Conclusions: Among patients receiving LVAD therapy, AKI and eGFR decline were common, and postoperative AKI was independently associated with eGFR decline and CKD progression at 90 and 365 days.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.